NASDAQ:AGRX - Agile Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$0.48 -0.03 (-5.88 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$0.51
Today's Range$0.47 - $0.53
52-Week Range$0.44 - $5.60
Volume599,304 shs
Average Volume396,408 shs
Market Capitalization$18.49 million
P/E Ratio-0.56
Dividend YieldN/A
Beta1.8

Headlines

Agile Therapeutics (NASDAQ AGRX) News Headlines

Source:
DateHeadline
Agile Therapeutics Inc (AGRX) Short Interest UpdateAgile Therapeutics Inc (AGRX) Short Interest Update
www.americanbankingnews.com - July 15 at 1:32 AM
Agile Therapeutics (AGRX) versus Chiasma (CHMA) Critical ReviewAgile Therapeutics (AGRX) versus Chiasma (CHMA) Critical Review
www.americanbankingnews.com - July 12 at 12:41 PM
-$0.17 Earnings Per Share Expected for Agile Therapeutics Inc (AGRX) This Quarter-$0.17 Earnings Per Share Expected for Agile Therapeutics Inc (AGRX) This Quarter
www.americanbankingnews.com - July 11 at 10:12 PM
Form 8-K AGILE THERAPEUTICS INC For: Jul 02Form 8-K AGILE THERAPEUTICS INC For: Jul 02
www.streetinsider.com - July 10 at 4:58 PM
Benzingas Daily Biotech Pulse: Titans Parkinsons Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% PremiumBenzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium
www.msn.com - July 3 at 8:49 AM
Agile Therapeutics Inc (AGRX) Given Consensus Recommendation of "Hold" by BrokeragesAgile Therapeutics Inc (AGRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 3 at 7:52 AM
Free Technical Research on Akorn and Three More Generic Drugs EquitiesFree Technical Research on Akorn and Three More Generic Drugs Equities
finance.yahoo.com - June 25 at 8:39 AM
AGRX: Files Formal Dispute Resolution with the FDAAGRX: Files Formal Dispute Resolution with the FDA
finance.yahoo.com - June 8 at 5:31 PM
Agile Therapeutics Inc (AGRX) Receives Average Rating of "Buy" from AnalystsAgile Therapeutics Inc (AGRX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - June 8 at 5:41 AM
Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash GuidanceAgile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance
finance.yahoo.com - June 7 at 5:25 PM
Agile Therapeutics Inc (AGRX) Expected to Post Earnings of -$0.17 Per ShareAgile Therapeutics Inc (AGRX) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - June 7 at 2:10 PM
Agile Therapeutics Inc (AGRX) Expected to Post Q3 2018 Earnings of ($0.15) Per ShareAgile Therapeutics Inc (AGRX) Expected to Post Q3 2018 Earnings of ($0.15) Per Share
www.americanbankingnews.com - May 25 at 7:00 AM
Agile Therapeutics Inc to Post FY2019 Earnings of ($0.64) Per Share, Cantor Fitzgerald Forecasts (AGRX)Agile Therapeutics Inc to Post FY2019 Earnings of ($0.64) Per Share, Cantor Fitzgerald Forecasts (AGRX)
www.americanbankingnews.com - May 24 at 9:38 AM
AGRX: Determining a Path Forward Following Receipt of Meeting MinutesAGRX: Determining a Path Forward Following Receipt of Meeting Minutes
finance.yahoo.com - May 22 at 5:09 PM
Agile Therapeutics Is Attempting A Hail Mary Play With A Formal Dispute ResolutionAgile Therapeutics Is Attempting A Hail Mary Play With A Formal Dispute Resolution
seekingalpha.com - May 21 at 5:10 PM
Royal Bank of Canada Cuts Agile Therapeutics (AGRX) Price Target to $3.00Royal Bank of Canada Cuts Agile Therapeutics (AGRX) Price Target to $3.00
www.americanbankingnews.com - May 21 at 11:24 AM
Agile Therapeutics (AGRX) PT Set at $4.00 by HC WainwrightAgile Therapeutics (AGRX) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - May 21 at 11:05 AM
Today’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead PharmaceuticalsToday’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals
finance.yahoo.com - May 21 at 8:15 AM
Agile Therapeutics (AGRX) Stock Rating Lowered by ValuEngineAgile Therapeutics (AGRX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 18 at 11:48 PM
Agile Therapeutics (AGRX) Announces Regulatory Update on Twirla; FDA Continues to have Significant ConcernsAgile Therapeutics (AGRX) Announces Regulatory Update on Twirla; FDA Continues to have Significant Concerns
www.streetinsider.com - May 18 at 6:01 PM
Agile Therapeutics down 76% on additional work needed for U.S. approval of TwirlaAgile Therapeutics down 76% on additional work needed for U.S. approval of Twirla
seekingalpha.com - May 18 at 6:01 PM
Agile Therapeutics sinks after FDA feedback on contraceptiveAgile Therapeutics sinks after FDA feedback on contraceptive
finance.yahoo.com - May 18 at 6:01 PM
Consolidated Research: 2018 Summary Expectations for Verint, Mesabi Trust, Clearwater Paper, AgileConsolidated Research: 2018 Summary Expectations for Verint, Mesabi Trust, Clearwater Paper, Agile
www.nasdaq.com - May 18 at 8:39 AM
Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of PregnancyAgile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy
finance.yahoo.com - May 18 at 8:39 AM
Agile Therapeutics (AGRX) Provides Twirla Update; Says FDA Has Significant Concerns Regarding the Adhesion of TwirlaAgile Therapeutics (AGRX) Provides Twirla Update; Says FDA Has Significant Concerns Regarding the Adhesion of Twirla
www.streetinsider.com - May 18 at 8:39 AM
Agile Therapeutics to Post FY2018 Earnings of ($0.80) Per Share, Zacks Investment Research Forecasts (AGRX)Agile Therapeutics to Post FY2018 Earnings of ($0.80) Per Share, Zacks Investment Research Forecasts (AGRX)
www.americanbankingnews.com - May 16 at 8:19 AM
AGRX: Waiting on Meeting Minutes from FDA; Planning for 2Q18 Twirla® NDA ResubmissionAGRX: Waiting on Meeting Minutes from FDA; Planning for 2Q18 Twirla® NDA Resubmission
finance.yahoo.com - May 14 at 5:21 PM
Agile Therapeutics (AGRX) Given Consensus Recommendation of "Hold" by BrokeragesAgile Therapeutics (AGRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 14 at 5:49 AM
Have Investors Priced In Agile Therapeutics Inc’s (NASDAQ:AGRX) Growth?Have Investors Priced In Agile Therapeutics Inc’s (NASDAQ:AGRX) Growth?
finance.yahoo.com - May 12 at 8:24 AM
HC Wainwright Reiterates $8.00 Price Target for Agile Therapeutics (AGRX)HC Wainwright Reiterates $8.00 Price Target for Agile Therapeutics (AGRX)
www.americanbankingnews.com - May 9 at 5:12 PM
Agile Therapeutics (AGRX) Releases Quarterly  Earnings Results, Hits ExpectationsAgile Therapeutics (AGRX) Releases Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - May 8 at 8:20 AM
Agile Therapeutics Reports First Quarter 2018 Financial ResultsAgile Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 7 at 5:38 PM
Agile Therapeutics: 1Q Earnings SnapshotAgile Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:38 PM
Agile Therapeutics (AGRX) Raised to Sell at ValuEngineAgile Therapeutics (AGRX) Raised to Sell at ValuEngine
www.americanbankingnews.com - May 4 at 3:35 PM
-$0.19 Earnings Per Share Expected for Agile Therapeutics (AGRX) This Quarter-$0.19 Earnings Per Share Expected for Agile Therapeutics (AGRX) This Quarter
www.americanbankingnews.com - May 3 at 8:22 PM
When Can We Expect A Profit From Agile Therapeutics Inc (NASDAQ:AGRX)?When Can We Expect A Profit From Agile Therapeutics Inc (NASDAQ:AGRX)?
finance.yahoo.com - May 3 at 8:16 AM
Agile Therapeutics (AGRX) Given Consensus Rating of "Hold" by AnalystsAgile Therapeutics (AGRX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 19 at 5:45 AM
Agile Therapeutics (AGRX) Earns Buy Rating from Analysts at HC WainwrightAgile Therapeutics (AGRX) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - April 17 at 12:04 AM
Agile Therapeutics (AGRX) Expected to Announce Earnings of -$0.19 Per ShareAgile Therapeutics (AGRX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 16 at 1:10 PM
Noble Financial Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)Noble Financial Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - April 15 at 9:45 AM
HC Wainwright Reaffirms Buy Rating for Agile Therapeutics (AGRX)HC Wainwright Reaffirms Buy Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - April 8 at 3:15 PM
Cantor Fitzgerald Comments on Agile Therapeutics FY2019 Earnings (AGRX)Cantor Fitzgerald Comments on Agile Therapeutics' FY2019 Earnings (AGRX)
www.americanbankingnews.com - April 6 at 8:23 AM
Agile Therapeutics (AGRX) Expected to Post Earnings of -$0.20 Per ShareAgile Therapeutics (AGRX) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 30 at 3:10 PM
What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?
finance.yahoo.com - March 28 at 5:19 PM
Pre-Market Technical Scan on Generic Drugs Equities -- Adamas Pharma, Agile Therapeutics, Catalent, and Diplomat PharmacyPre-Market Technical Scan on Generic Drugs Equities -- Adamas Pharma, Agile Therapeutics, Catalent, and Diplomat Pharmacy
www.prnewswire.com - March 26 at 8:22 AM
Agile Therapeutics (AGRX) Given Consensus Recommendation of "Hold" by AnalystsAgile Therapeutics (AGRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 25 at 5:32 AM
New Research: Key Drivers of Growth for At Home Group, Griffon, Mitek, J & J Snack Foods, Lindsay, and Agile Therapeutics — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for At Home Group, Griffon, Mitek, J & J Snack Foods, Lindsay, and Agile Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - March 23 at 8:18 AM
Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future?Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future?
finance.yahoo.com - March 20 at 5:18 PM
Agile Therapeutics (AGRX) Receives "Buy" Rating from Noble FinancialAgile Therapeutics (AGRX) Receives "Buy" Rating from Noble Financial
www.americanbankingnews.com - March 15 at 6:44 PM
Agile Therapeutics Inc (AGRX) Forecasted to Earn Q1 2018 Earnings of ($0.19) Per ShareAgile Therapeutics Inc (AGRX) Forecasted to Earn Q1 2018 Earnings of ($0.19) Per Share
www.americanbankingnews.com - March 15 at 7:36 AM
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.